6794.TW UnicoCell Biomed Co., Ltd.
- Market cap
- TWD 4.10B
- P/E
- -
- P/B
- 5.01x
- ROE
- -11.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6794.TW undervalued?
Graham numberThe Graham number of UnicoCell Biomed Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
UnicoCell Biomed Co., Ltd. fundamental analysis
No fundamental analysis for UnicoCell Biomed Co., Ltd. yet.
UnicoCell Biomed Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing …
Full company profileUnicoCell Biomed Co., Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
UnicoCell Biomed Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 5.99M | 5.49M | 15.7M | 3.98M | 8.18M | 14.4M | 24.6M | 31.9M | 30.1M | 21.7M |
| Gross Profit | 4.95M | 4.20M | 12.5M | 2.34M | 5.83M | 8.20M | 17.9M | 20.6M | -221K | 13.5M |
| Operating Income | -44.2M | -69.0M | -101M | -108M | -87.3M | -92.1M | -96.3M | -103M | -130M | -111M |
| EBITDA | -39.4M | -63.6M | -79.1M | -84.6M | -59.4M | -65.6M | -56.3M | -64.0M | -110M | -77.7M |
| Net Income | -42.9M | -40.5M | -101M | -109M | -86.4M | -91.2M | -84.1M | -93.1M | -115M | -96.3M |
| EPS | -3.94 | -2.51 | -3.30 | -3.05 | -2.29 | -2.20 | -1.56 | -1.57 | -1.89 | -1.51 |
| Balance Sheet | ||||||||||
| Total Assets | 141M | 286M | 356M | 391M | 298M | 414M | 686M | 778M | 946M | 895M |
| Total Liabilities | 4.16M | 13.1M | 61.9M | 47.8M | 34.7M | 80.5M | 89.5M | 93.3M | 80.6M | 76.8M |
| Shareholders' Equity | 137M | 273M | 294M | 343M | 263M | 334M | 596M | 685M | 865M | 819M |
| Cash & Short-term Investments | 123M | 253M | 236M | 232M | 141M | 214M | 477M | 554M | 752M | 710M |
| Total Debt | - | - | 44.7M | 34.0M | 21.6M | 66.6M | 74.3M | 68.2M | 62.0M | 58.9M |
| Cash Flow | ||||||||||
| Operating Cash Flow | -42.4M | -58.0M | -77.2M | -92.2M | -61.7M | -63.6M | -65.5M | -61.5M | -91.3M | -76.5M |
| Capital Expenditure | 1.94M | 10.4M | 50.8M | 56.8M | 24.0M | 14.6M | 16.0M | 5.71M | 5.50M | 2.35M |
| Free Cash Flow | -44.3M | -68.4M | -128M | -149M | -85.7M | -78.2M | -81.5M | -67.2M | -96.8M | -78.9M |
| Ratios | ||||||||||
| ROE | -31.3% | -14.8% | -34.3% | -31.8% | -32.8% | -27.3% | -14.1% | -13.6% | -13.3% | -11.8% |
| ROA | -30.3% | -14.2% | -28.3% | -27.9% | -29.0% | -22.0% | -12.3% | -12.0% | -12.1% | -10.7% |
| Net Profit Margin | -717.1% | -737.6% | -641.4% | -2,742.6% | -1,056.3% | -633.2% | -342.1% | -291.9% | -381.5% | -442.6% |
| Debt to Equity | - | - | 0.15x | 0.10x | 0.08x | 0.20x | 0.12x | 0.10x | 0.07x | 0.07x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
UnicoCell Biomed Co., Ltd. dividends
UnicoCell Biomed Co., Ltd. has not paid dividends in the last 9 fiscal years.
Who owns UnicoCell Biomed Co., Ltd.
- Insiders 56.62%
- Institutions 0.00%
- Public & others 43.38%
- Shares outstanding 63.6M
- Free float 26.6M
UnicoCell Biomed Co., Ltd. company profile
- Company name
- UnicoCell Biomed Co., Ltd.
- Ticker
- 6794.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- December
- Address
- No. 13-20, Minquan East Road, Taipei, Taiwan, 11494
- Phone
- 886 2 2792 2699
- Website
- unicocell.com
About UnicoCell Biomed Co., Ltd.
UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests, as well as contract development and manufacturing organization (CDMO) services for cell-based products. UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.
UnicoCell Biomed Co., Ltd. management
5- Mr. Yi-Pei HungGeneral Manager
- Pei-Lin ChenCFO & Corporate Governance Officer
- Mr. Lin Chen-YuAssistant Vice President
- Ms. Ting WangAssistant Vice President
- Jui-Yu LiuAccounting Supervisor & Chief Internal Auditor